Thursday, October 15, 2026

BTC $80,624 ▼ 1.17%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

ADA$0.220−4.27%ETH$2,351−2.81%LINK$12.00−3.38%SOL$101.85−2.25%BTC$80,624−1.17%XRP$1.30−2.43%S&P 5007,719−1.11%Nasdaq26,693−1.88%Dow51,621−0.09%RUT2,730−1.93%TNX5.19%−0.52%TYX5.53%−0.68%FVX4.99%−0.30%IRX4.08%+0.69%VIX16.87+10.48%GOLD$4,159.40+1.25%SILVER$56.06+0.32%OIL$94.04−1.10%DXY102.06−0.48%NVDA$221.30−3.16%AAPL$342.96+0.50%TSLA$367.16−2.15%META$737.54−3.27%MSFT$533.69−1.80%AMZN$254.08−1.74%GOOGL$347.64−1.74%Fear & Greed53 — NeutralADA$0.220−4.27%ETH$2,351−2.81%LINK$12.00−3.38%SOL$101.85−2.25%BTC$80,624−1.17%XRP$1.30−2.43%S&P 5007,719−1.11%Nasdaq26,693−1.88%Dow51,621−0.09%RUT2,730−1.93%TNX5.19%−0.52%TYX5.53%−0.68%FVX4.99%−0.30%IRX4.08%+0.69%VIX16.87+10.48%GOLD$4,159.40+1.25%SILVER$56.06+0.32%OIL$94.04−1.10%DXY102.06−0.48%NVDA$221.30−3.16%AAPL$342.96+0.50%TSLA$367.16−2.15%META$737.54−3.27%MSFT$533.69−1.80%AMZN$254.08−1.74%GOOGL$347.64−1.74%Fear & Greed53 — Neutral

Tag

retatrutide

2 articles

U.S. Equities15d ago

Eli Lilly's Retatrutide Shows 20.8% Weight Loss at Top Dose; BLA Due Q1 2027

Triple agonist achieves dose-dependent weight reductions up to 49.6 pounds and A1C drops to 5.7% in 40% of patients, clearing path for 2027 market entry.

U.S. Equities83d ago

Eli Lilly's Retatrutide FDA Bid Targets $25B Peak Sales in $100B Obesity Market

Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.